‘Real World’ Data on Costs With CAR-T Cell Therapy
The formidable price tag of the new chimeric antigen receptor (CAR) T-cell therapies has sent shock waves through the blood cancers community, which is struggling to incorporate this novel approach because of the remarkable responses that have been seen. But the price tags — enormous as they are (nearly half a million [$475,000] for tisagenlecleucel [Kymriah, Novartis]